Isoflon (Itraconazole)

Isoflon (itraconazole) is indicated for systemic fungal infections affecting various organ systems.

• Blastomycosis: treatment of infection caused by Blastomyces dermatitidis, reducing disease severity.
• Histoplasmosis: therapy for disseminated histoplasma infection, improving clinical outcomes.
• Aspergillosis: management of invasive aspergillus disease, aiding fungal clearance.
• Candidiasis: treatment of oropharyngeal and esophageal candidiasis, relieving symptoms.
• Sporotrichosis: therapy for cutaneous and systemic sporotrichosis, promoting lesion healing.
• Dermatophytosis: treatment of extensive or refractory dermatophyte skin infections, achieving eradication.

• Itraconazole exerts its antifungal activity by inhibiting the fungal cytochrome P450 enzyme lanosterol 14α‑demethylase. This blockade prevents conversion of lanosterol to ergosterol, a vital component of the fungal cell membrane. The resulting depletion of ergosterol disrupts membrane integrity and impairs cell growth, leading to fungistatic or fungicidal effects depending on concentration and organism.

Itraconazole may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: transient cranial discomfort.
• Abdominal pain: occasional cramping or discomfort.
• Rash: mild skin irritation or erythema.
• Taste disturbance: altered taste perception.
• Elevated liver enzymes: mild, often reversible.

Serious or Rare Side Effects

• Hepatotoxicity: potential liver injury requiring monitoring.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiac failure: rare cases of congestive heart failure.
• Visual disturbances: blurred vision or photophobia.
• Severe hypokalemia: low potassium levels, especially with concomitant diuretics.

When prescribing Isoflon, clinicians should consider several precautionary measures to ensure safe use.

• Liver function monitoring: assess baseline hepatic enzymes and repeat periodically during therapy.
• Drug‑induced QT prolongation: avoid in patients with known cardiac arrhythmias or concomitant QT‑prolonging agents.
• Concomitant CYP3A4 substrates: adjust doses of drugs metabolized by CYP3A4 to prevent toxicity.
• Pregnancy and lactation: use only if potential benefit justifies risk; limited data available.
• Patient counseling: advise on possible gastrointestinal upset and importance of adherence.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Itraconazole has a notable interaction profile that requires careful review of co‑medications.

Major Interactions (Avoid)

• Rifampin: strong inducer of CYP3A4, markedly reduces itraconazole levels.
• Antacids containing aluminum or magnesium: decrease absorption of itraconazole.
• Ketoconazole: additive hepatotoxicity risk when combined.
• St. John’s wort: induces metabolism, lowering itraconazole efficacy.

Moderate Interactions (Monitor Closely)

• Statins (e.g., simvastatin): increased risk of myopathy.
• Calcium channel blockers (e.g., verapamil): may increase itraconazole concentrations.
• Oral contraceptives: reduced effectiveness, consider alternative contraception.